在线客服系统
 
招聘信息  |  中文版  |  ENGLISH
    首页 > 新闻中心
    快速导航
  公司简介
  公司动态
  合作伙伴
 
中国客户采用Simulations Plus 软件发表的部分文献
2016-07-21

英文文献

 

001 Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.  IF= 2.465
Wang L, Liu F, Jiang N, Zhou W, Zhou X, Zheng Z. (2016) Molecules , 21(6), 772. 

 

002 PBPK modeling and simulation in drug research and development.  IF=3.138
Zhuang X, Lu C. (2016) Acta Pharmaceutica Sinica B June 23

 

003 Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.
Yang B, Wu C, Ji B, Wu M, He Z, Shang L, Sun J. (2016) Asian J. Pharm. Sci. Mar 21

004 Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.  IF=3.35

Wang B, Liu Z, Li D, Yang S, Hu J, Chen H, Sheng L, Li Y. (2015) Eur J Pharm Sci. Jun 24

005 Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.   IF=2.42
Chen Y, Liu Z, Fu T, Li W, Xu X, Sun H. Bioorg. & Med. Chem. Lett., 2015, 25, 3442-3446.

006 Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.   IF=2.912
Gao ZW Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF. (2015) Acta Pharmacol Sin. Dec; 36(12):1528-36.

 

007 Discovery of new scaffolds from approved drugs asacetylcholinesterase inhibitors. IF=5.583

Chen Y, Xu X,Fu T, Li W, Liu Z, Sun H. (2015) RSC Advances, 10(39):90288-90294

 

008 Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.  IF=1.26

Zhu L, Yang J, Zhang Y, Wang Y, Zhang J, Zhao Y, Dong W. (2015) Korean J Physiol Pharmacol. Mar;19(2):99-104.

009 Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.   IF=1.31

Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. (2015) Eur J Drug Metab Pharmacokinet. Mar10.

010 Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically-based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.  IF=2.09

Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. (2014) Biopharm Drug Dispos. Mar19.

 

011 Elucidation of Arctigenin Pharmacokinetics After Intravenous and Oral Administrations in Rats:Integration of In Vitro and In Vivo Findings via Semi-mechanistic Pharmacokinetic Modeling.  IF=4.39

Gao Q, Zhang Y, Wo S, Zuo Z. (2014) AAPS J. Oct. 2

 

012 Interspecies prediction of oral pharmacokinetics of different formulations from dogs to human:physiologically based pharmacokinetic modelling combined with biorelevant dissolution.  IF=3.71

Wu C, Kou L, Ma P, Gao L, Li B, Li R, Luo C, Shentu J, Hea Z, Sun J. (2015) RSC Adv. 5:19844

 

013 Profiling Biopharmaceutical Deciding Properties of Absorption of Lansoprazole Enteric-Coated Tablets Using Gastrointestinal Simulation Technology.  IF=3.99

Wu C, Sun L, Sun J, Yang Y, Ren C, Ai X, Lian H, He Z. (2013) Int J Pharm. Jun 24

 

014  A Computational Drug-Target Network for Yuanhu Zhitong Prescription. IF= 1.722

Xu H, Tao Y, Lu P, Wang P, Zhang F, Yuan Y, Wang S, Xiao X, Yang H, Huang L. (2013)

Evidence-Based Complementary and Alternative Medicine, Article ID 658531

 

015 Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.  IF=2.35

Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. (2012) Acta Pharmacol Sin. Oct. 22

 

 

中文文献

 

001淡墨,闻镍,刘丽等. 雷公藤甲素诱导正常人肝细胞L02的毒性及甘草酸二铵的保护作用[J].药物分析杂志2015, 35( 9)1568-1573


002
淡墨,闻镍,刘丽等. 甘草酸二铵通过上调CYP3A4 拮抗雷公藤甲素诱导肝细胞毒性[J]. 中国新药杂志2015, 24(12): 1349-1357

 

003 晨,李进,冯艳春等. 头孢地尼有关物质定量结构色谱保留模型的建立[J]. 药学学报2015, 50(9): 1161-1166

 

004刘家宝,朱立勤,章袁等. 阿托伐他汀生理药动学模型的建立[J]. 中国医院药学杂志2015, 35(16): 1465-1469

005许羚,李禄金,王鲲等. 新药早期临床试验中的定量药理学方法[J]. 中国新药杂质2015, 24(1): 52-58

 

006郑永勇,解鹏,张瑾等. 芳基哌嗪苯并噁嗪类化合物的设计、合成及生物活性研究[J]. 药学学报2012, 47 (6): 755763

 

007潘瑞雪,高源,陈万里等. 溶出度实验结合计算机模拟技术评价国产阿莫西林胶囊的生物等效性[J]. 药学学报2014, 49 (8): 1155 1161

 

008 潘瑞雪,余方键,邹文博等. GastroPlus 软件模拟技术评价头孢地尼胶囊制剂的有效性[J]. 中国新药杂志2014, 23(13): 1506-1513

 

009 胡昌勤,潘瑞雪. 溶出度试验评价/预测固体口服制剂生物等效性的研究进展[J]. 中国新药杂志 2014, 23(1): 44-51

 

010 于明明,高志伟,陈笑艳等. 采用生理药动学模型预测抗肿瘤新药法米替尼在人体中的药动学[J]. 药学学报2014, 49 (12): 1684 1688

 

011 李小东,陈悦,李煜等. 采用GastroPlusTM 软件评估甲磺酸多沙唑嗪缓释片的体内外溶出特征[J]. 中国现代应用药学2016, 33(1): 71-75

 

 

硕博士论文

 

001 吴亮. 应用生理药动学模型对甲氨蝶呤在儿童体内药动学的预测及验证[D]. 四川: 西南交通大学研究生学位论文

 

002 杨建伟. 莫西沙星在腹腔感染大鼠中的药动学和药效学及种属间的外推研究[D]. 天津:天津医科大学硕士学位论文

 

003 安佃云. 磷酸川芎嗪渗透泵片应用Gastro PlusTM软件的模拟及处方优化[D]. 山东:山东中医药大学硕士学位论文

 

004 潘瑞雪. 溶出度实验结合计算机模拟技术评价国产β-内酰胺类抗生素的生物等效性[D]. 北京:中国食品药品检定研究院硕士研究生学位论文

 

005 孙乐. 基于BCS系统的in silico/in vitro模型评价药物及制剂的BA/BE [D]. 沈阳:沈阳药科大学博士学位论文

 

006 姜伟明. Gastro PlusTM软件在药物模型构建、人体血浆清除率预测和临床试验处方设计中的应用[D]. 上海:上海交通大学硕士学位论文

 

 

 
返回